QURE: uniQure N.V. Cash per Share

uniQure N.V. dominates hemophilia B gene therapy, ensuring high margins. The cash per share metric demonstrates current liquidity, where the parameter equals 9.50. However, fierce patent battles with biotech behemoths create risks. To minimize dependency, uniQure N.V. combines in-house capacities with the delegation of final trials to external contractors.
Analytical breakdowns for uniQure N.V.

This indicator determines the volume of liquid assets per security, allowing for an assessment of the company's internal financial reserve for autonomous development without external borrowing. An analysis of the cash per share metric confirms the ability of uniQure N.V. (QURE) to maintain its own high-tech manufacturing facility in Lexington, which minimizes operational risks and enhances the asset's fundamental stability.